Amgen Reports First Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Amgen (AMGN) PT Lowered to $183 at RBC Capital
April 25, 2018 7:41 AM EDTRBC Capital lowered its price target on Amgen (NASDAQ: AMGN) to $183.00 (from $189.00) while maintaining a Sector Perform rating.
Analyst Kennen MacKay said AMGN's surprise Q1:18 top and bottom line beats are tempered by legacy base business products largely driving the revenue beat.
... MoreAmgen (AMGN) Tops Q1 EPS by 23c; Boosts Outlook
April 24, 2018 4:02 PM EDTAmgen (NASDAQ: AMGN) reported Q1 EPS of $3.47, $0.23 better than the analyst estimate of $3.24. Revenue for the quarter came in at $5.6 billion versus the consensus estimate of $5.43 billion.
2018 EPS guidance revised to $11.30-$12.28 on a GAAP basis and $12.80-$13.70 on a non-GAAP basis (*** consensus is $13.48); total revenues guidance revised to $21.9-$22.8 billion (*** consensus is $22.61 billion).
"Amgen's strong first-quarter performance was driven by our new and recently launched products, all of which delivered double-digit, volume-driven growth," said Robert A. Bradway, chairman and chief executive officer. "We look... More
